New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 18, 2013
13:21 EDTCEA, BCRX, ZNH, YUM, GSKBird-flu may add risks to China slowdown, Bloomberg says
China’s bird-flu outbreak is affecting businesses from restaurants to travel, according to Bloomberg, citing a note to investors this week from Goldman Sachs that said the outbreak “may suppress domestic consumption in the near term." Bloomberg outlined the potential on a number of publicly-traded companies, including Yum! Brands (YUM), China Southern Airlines (ZNH) and China Eastern Airlines (CEA). The Fly notes companies developing bird flu vaccines include BioCryst (BCRX) and Glaxo (GSK). Reference Link
News For YUM;BCRX;GSK;ZNH;CEA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 4, 2016
09:51 EDTYUMYum! Brands: Economics in China 'not what they used to be'
09:39 EDTYUMYum! Brands says 2H operating profit to be 'directionally stronger' than 1H
Subscribe for More Information
09:24 EDTYUMYum! Brands sees China SSS up low single digits in Q1
Subscribe for More Information
07:23 EDTGSKGSK will not be pressured into early consumer unit spinoff, Reuters says
Subscribe for More Information
06:15 EDTYUMYum! Brands names David Russell as interim CFO
Subscribe for More Information
February 3, 2016
16:24 EDTYUMYum! Brands reports Q4 China KFC SSS up 6%
Reports Q4 China Pizza Hut Casual Dining SSS down 8%.
16:22 EDTYUMYum! Brands backs FY16 ex-currency operating profit growth 10%
Subscribe for More Information
16:20 EDTYUMYum! Brands says China spin-off 'on track'
Subscribe for More Information
16:20 EDTYUMYum! Brands sees opening nearly 2,400 locations in 2016
Subscribe for More Information
16:19 EDTYUMYum! Brands reports China SSS up 2%
Subscribe for More Information
16:16 EDTYUMYum! Brands reports Q4 adjusted EPS 68c, consensus 66c
Reports Q4 revenue $3.95B, consensus $4.02B.
14:48 EDTYUMNotable companies reporting after market close
Subscribe for More Information
12:22 EDTYUMYum! Brands technical notes ahead of results
Subscribe for More Information
07:23 EDTGSKGlaxoSmithKline confirms 2015 ordinary dividend of 80p, special dividend of 20p
Subscribe for More Information
07:23 EDTGSKGlaxoSmithKline sees double digits CER FY16 core EPS percentage growth
If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth.
07:21 EDTGSKGlaxoSmithKline reports Q4 EPS (7.3p) vs. 21.5p last year
Subscribe for More Information
05:59 EDTYUMYum! Brands volatility elevated into Q4 and outlook
Yum! Brands February weekly call option implied volatility is at 86, February is at 44, March is at 34; compared to its 52-week range of 19 to 47, suggesting large near term price movement into the expected release of Q4 results today.
February 2, 2016
08:17 EDTGSKAdaptimmune, GSK expand strategic immunotherapy collaboration
Adaptimmune Therapeutics (ADAP) and GlaxoSmithKline (GSK) announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune's lead clinical cancer program, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1, toward pivotal trials in synovial sarcoma. Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.
07:42 EDTGSKPressure mounts on big pharma names to shrink, sharpen focus, FT says
Subscribe for More Information
06:32 EDTGSKGSK, J&J back Index Ventures' $1B biotech business spinoff, Reuters says
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) will back a new spinoff from Index Ventures, which is spinning off its biotech portfolio into a new $1B entity, Reuters reports. The New Medicxi Ventures business will be helmed by the existing life sciences team from Index and will include all the current biotech portfolio firms, the report says. Medicxi raises $229M for a new fund in Europe with GSK and J&J each putting in 25%, Reuters reports. Reference Link
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use